Sotrastaurin

For research use only. Not for use in humans.

目录号:S2791 别名: AEB071

Sotrastaurin Chemical Structure

CAS No. 425637-18-9

Sotrastaurin (AEB071) 是一种有效的,选择性的泛PKC抑制剂,最有效作用于PKCθ,无细胞试验中Ki为0.22 nM;对PKCζ没有活性。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1566.89 现货
RMB 1414.55 现货
RMB 5468.97 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Sotrastaurin发表文献36篇:

产品安全说明书

PKC抑制剂选择性比较

生物活性

产品描述 Sotrastaurin (AEB071) 是一种有效的,选择性的泛PKC抑制剂,最有效作用于PKCθ,无细胞试验中Ki为0.22 nM;对PKCζ没有活性。Phase 2。
特性 同以往的PKC抑制剂不同,AEB071并不会在激活诱导的细胞死亡模型中增强鼠T细胞原幼细胞的凋亡。
靶点
PKCθ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCα [1]
(Cell-free assay)
PKCη [1]
(Cell-free assay)
PKCδ [1]
(Cell-free assay)
0.22 nM(Ki) 0.64 nM(Ki) 0.95 nM(Ki) 1.8 nM(Ki) 2.1 nM(Ki)
体外研究

在人和鼠的早期T细胞中,毫微摩尔级浓度的AEB071 (< 10μM)则能有效消除早期T细胞激活的信号如白介素-2分泌物和CD25表达。在没发生非特异性抗增殖的效应的细胞中,AEB071 (200 nM)能抑制CD3/CD28抗体和同种抗原诱导的T瞎报增殖反应。AEB071(<3 μM)可以显著抑制淋巴细胞功能相关抗原1介导的T细胞的粘附作用。[1] AEB071(< 20 μM)特异性地降低CD79突变体ABC DLBCL细胞系的增殖,随之能减少NF-κB信号活性。3 μM 浓度的AEB071可诱导CD79突变细胞在G1阻断和/或细胞坏死。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T cell NFfVe2VHfW6ldHnvckBCe3OjeR?= M2nUW|ExOCCwTR?= M{\BUVMhcA>? M4HjUWROW09? NH24UG1qdmirYnn0d{BzWk6DIIP5cpRp\XOrcx?= M{m2e|I2PjlzMUW4
HUVECs  MYPGeY5kfGmxbjDBd5NigQ>? NFjabo82ODCwTR?= M1vDblEhcA>? NHniUZZT\WS3Y3XzJGRVYC2Wcnnn[4Vz\WRiRX7kc5Rp\WyrYXygSJl{\nWwY4Tpc44> NFjsOlYzPTZ|NEWzPC=>
A549 NWD4VVhmTnWwY4Tpc44hSXO|YYm= NX;DWYlHOC5zwrFOwG0> MUGyOEBp M1LBVIRm[3KnYYPld{B1cGVicnXsZZRqfmViUFvDMe6yKGyndnXsJI9vKGOnbHygcYVu[nKjbnWgZ491emWjdHXkJGFUNUmY M2e3V|I2OjF6MU[x
A549 NFj4eZRHfW6ldHnvckBCe3OjeR?= M4DzZVAvOcLizszN MlPJNlQhcA>? MXzy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKGyndnXsd{Bw\iCPTWCtNkwhVU2SLUmgZY5lKGmwdHXndolvKM7{MR?= MoqzNlUzOThzNkG=
A549 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof0NE4yyqEQvF2= M4ixSlI1KGh? NIPMUVhmdmijbnPld{Boem:5dHigbY5pcWKrdHnvckBkd3S{ZXH0[YQhf2m2aDDBV{1KXg>? MVWyOVIyQDF4MR?=
Mel202 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrSNE42KM7:TR?= M4PBflMhcA>? MV7EUXNQ M{nEPIVvcGGwY3XzJGlTNWmwZIXj[YQhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6 M170SlI1PTl3M{i1
92.1 M2nUZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoniNE42KM7:TR?= NFjUSWw{KGh? MXXEUXNQ M1zmSIVvcGGwY3XzJGlTNWmwZIXj[YQhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6 MX6yOFU6PTN6NR?=
OCM3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fx[lAvPSEQvF2= MWizJIg> M4j5dGROW09? MXLlcohidmOnczDJVk1qdmS3Y3XkJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fS=> NWPBfWVsOjR3OUWzPFU>
Mel202 NH3nVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojONE42KM7:TR?= M1qyNFMhcA>? NXrQWphMTE2VTx?= MmXvbY5kemWjc3XzJGlTNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5TDqA>? NVPGRoNoOjR3OUWzPFU>
92.1 M{Wwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DqVVAvPSEQvF2= NIDFcoY{KGh? NX7DTYdvTE2VTx?= MmLCbY5kemWjc3XzJGlTNWmwZIXj[YQh[2WubDDjfYNt\SCjcoLld5TDqA>? M4jsflI1PTl3M{i1
OCM3 NGPIRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPnWmhHOC53IN88US=> NULmSppHOyCq MXHEUXNQ MWrpcoNz\WG|ZYOgTXIucW6mdXPl[EBk\WyuIHP5Z4xmKGG{cnXzeOKh NILtVGMzPDV7NUO4OS=>
Jeko-1 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmL5NE01KM7:TR?= M4fxV2ROW09? Mn3nbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M{X4U|I1OzZ{OUO1
Mino M2r6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C3NlAuPCEQvF2= MXrEUXNQ M3TuUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NX60WXk6OjR|NkK5N|U>
Rec-1 NHjxOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\oRXYxNTRizszN M1jrVGROW09? NXnpfIs1cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NWjyOo85OjR|NkK5N|U>
SP49 M{j5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfSNE01KM7:TR?= NUG3cHpXTE2VTx?= NWPKS2xCcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NIHzUm0zPDN4MkmzOS=>
Jeko-1 MmjnSpVv[3Srb36gRZN{[Xl? M3e4VlIvPSEQvF5CpC=> M2r0VVEzKGh? Mki5SG1UVw>? Mnna[I94dnKnZ4XsZZRmeyCQRj5OvmIhfGG{Z3X0JIdmdmW| NU\1NVJHOjR|NkK5N|U>
Mino M2rMW2Z2dmO2aX;uJGF{e2G7 Mmq1Nk42KM7:TdMg MlrGNVIhcA>? NYHqU2RUTE2VTx?= NGi5XIxld3ewcnXneYxifGW|IF7GMe67SiC2YYLn[ZQh\2WwZYO= MWmyOFM3Ojl|NR?=
Rec-1 MXPGeY5kfGmxbjDBd5NigQ>? NVLiNlllOi53IN88UeKh MoDRNVIhcA>? M3fFRmROW09? NIXjToRld3ewcnXneYxifGW|IF7GMe67SiC2YYLn[ZQh\2WwZYO= MY[yOFM3Ojl|NR?=
SP49 M3LQ[mZ2dmO2aX;uJGF{e2G7 NIn1T3ozNjVizszNxsA> NHzkXmcyOiCq NHS3U3pFVVOR MUfkc5dvemWpdXzheIV{KE6ILd86RkB1[XKpZYSg[4Vv\XN? MlvjNlQ{PjJ7M{W=
CD3+ T  NEG4WFJHfW6ldHnvckBCe3OjeR?= Mmr3NE02ODBibl2= NXXzSYtIOSCq NWLkWpk6cW6qaXLpeJMhVkZvzsrCJJBpd3OyaH;yfYxifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NVzp[5Z4OjN3N{OyPFM>
Mel202 NFvJcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\uPVdlOC13IN88US=> M1HEZVczKGh? MYrEUXNQ NVL2PIZNcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NF:zc4UzOjZ3M{m2PC=>
Omm1.3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPEWZgxNTVizszN MYe3NkBp NHH0UJFFVVOR MmLRbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NWPvSo1tOjJ4NUO5Olg>
92.1 NF76d5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMVUh|ryP M1\5VVczKGh? NH7lcI5FVVOR MlXHbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NYXqfY5MOjJ4NUO5Olg>
Mel202 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWi1JO69VQ>? Ml7WNlQhcA>? M3;vTWROW09? M1\3bIlv\HWlZYOgS|Eh[XK{ZYP0xsA> NVnx[oM6OjJ4NUO5Olg>
Omm1.3 NWHVOJFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fGT|Uh|ryP MX6yOEBp MV7EUXNQ NHu1NJVqdmS3Y3XzJGcyKGG{cnXzeOKh NInnco0zOjZ3M{m2PC=>
92.1 MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ToNFUh|ryP NFe0OYczPCCq MnLiSG1UVw>? NVntdllGcW6mdXPld{BIOSCjcoLld5TDqA>? MWWyNlY2Ozl4OB?=
Mel202 M{XjZWFxd3C2b4Ppd{BCe3OjeR?= NXruU2pmPSEQvF2= MlrZO|IhcA>? NGm5SnZFVVOR MY\pcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= M3ficVIzPjV|OU[4
Omm1.3 MUfBdI9xfG:|aYOgRZN{[Xl? NYmyZpJCPSEQvF2= M{jHelczKGh? M2rMRWROW09? MkHzbY5lfWOnczDhdI9xfG:|aYO= MVGyNlY2Ozl4OB?=
92.1 MYXBdI9xfG:|aYOgRZN{[Xl? MWq1JO69VQ>? M4f5UFczKGh? NXrSTHdnTE2VTx?= MorkbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoY3HueIx6 NYDoVpFzOjJ4NUO5Olg>
Mel202 MXLGeY5kfGmxbjDBd5NigQ>? MXe1JO69VQ>? NGS3VmQzPCCq MoH1bY5pcWKrdIOg[ZhxemW|c3nvckBidmRicHjvd5Bpd3K7bHH0bY9vKG:oIGDLR{Bqe2:ob4Ltdy=> NYHhcVBnOjJ4NUO5Olg>
Omm1.3 MnjtSpVv[3Srb36gRZN{[Xl? M4LzdFUh|ryP NX3CfG1zOjRiaB?= MUHpcohq[mm2czDlfJBz\XO|aX;uJIFv\CCyaH;zdIhwenmuYYTpc44hd2ZiUFvDJIl{d2[xcn3z MlXzNlI3PTN7Nki=
92.1 MW\GeY5kfGmxbjDBd5NigQ>? M{PJOFUh|ryP MWeyOEBp NInLOmFqdmirYnn0d{BmgHC{ZYPzbY9vKGGwZDDwbI9{eGixconsZZRqd25ib3[gVGtEKGm|b3\vdo1{ M{\tbFIzPjV|OU[4
HBL1 NG\kUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKwMlE3NTJyIN88US=> M4nHS|Uh\A>? M1zCVmlEPTB;MD61JO69VQ>? NWjoTVdiOjF|MkS5NlA>
TMD8 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzKVGsxNjF4LUKwJO69VQ>? MXu1JIQ> NF3UVZNKSzVyPUCuNkDPxE1? M1HoUFIyOzJ2OUKw
OCI-Ly10 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPv[nlYOC5zNj2yNEDPxE1? NF7pSZM2KGR? NInWXIhKSzVyPUGuN{DPxE1? NYG1UIJZOjF|MkS5NlA>
U2932 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXEepZROC5zNj2yNEDPxE1? NIfBRlM2KGR? MlPlTWM2OD1zMDFOwG0> M4PJNlIyOzJ2OUKw
OCI-Ly3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\lNE4yPi1{MDFOwG0> MV[1JIQ> M37mV2lEPTExvK6yNEDPxE1? MoSzNlE{OjR7MkC=
SuDHL2 NE\Fe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\tWFAvOTZvMkCg{txO NGjCZmc2KGR? NWPscYd1UUN3MP-8olIxKM7:TR?= NYrkOHk2OjF|MkS5NlA>
SuDHL4 M2TUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuwMlE3NTJyIN88US=> MV[1JIQ> NXvvV4N[UUN3MP-8olIxKM7:TR?= MWWyNVMzPDl{MB?=
DB NYm5SXJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSwMlE3NTJyIN88US=> MWi1JIQ> M4XrZ2lEPTExvK6yNEDPxE1? MXSyNVMzPDl{MB?=
Jurkat IL-2 MoHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPaVHJKSzVyPU[uO|EhyrFiMz63OkDPxE1? NVjuXZUyOTl7NECyOVk>
PBMC IL-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTRwOESgxtEhOS55MDCg{txO M{PYSlE6QTRyMkW5

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pPKCδ/θ / phosphorylated MARCKS / p53 / MDM2 / PUMA / p21; 

PubMed: 29593251     


Cell lines OMM2.3, OMM2.5 and OMM1 were treated with 8 µM Nutlin-3 and 4 µM Sotrastaurin. MEL290 was incubated with 2 µM Nutlin-3 and 4 µM Sotrastaurin, cell line MM28 with 8 µM Nutlin-3 and 1 µM Sotrastaurin, and cell lines MEL202, MEL270 and MM66 with 2䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣痖뙠ෆ€𢡄뙤ෆ€䀷痗뙤ෆ౴뙤ෆ㵶痗뙤ෆ뺖᎒泌Itemセ᎒Count﫨呂뚔ෆ猴፲뙤ෆ፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄堚Ѽ齃礤v�堞ﻮ᎒猢Wセ᎒䨼Ą鹿齃

Cyclin D1 / p27(Kip1) ; 

PubMed: 22653968     


AEB071 selectively increased p27 and decreased cyclin D1 expression in GNAQ mutant UM cells. Cells were treated with 0, 2, or 5 μM AEB071 for 72 hours and analyzed by immunoblot. WT = GNAQ wild type; MT = GNAQ mutation.

Bcl-xl / XIAP / Survivin ; 

PubMed: 22653968     


AEB071 decreased the expression of antiapoptotic proteins Bcl-xL, XIAP, and survivin in GNAQ mutated cells. WT = GNAQ wild type; MT = GNAQ mutation.

PKCα / PKCδ / PKCβ / PKCε / PKCθ ; 

PubMed: 22653968     


AEB071 inhibited PKC expression in UM cells. Cells were treated with 5 μM AEB071 for 24 hours in the presence of 10% FBS and subjected to immunoblot analysis. PKCδ, ε and θ levels in AEB treated cells relative to control (DMSO treated) cells are also show䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨Ղà㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ猴፲사Ղ፲씢痗猸፲髸莤䥷堙᎒

p-Marcks / p-ERK / p-AKT / p-S6 / Marcks / ERK / AKT / S6; 

PubMed: 22653968     


AEB071 inhibits PKC and mTOR pathways but not AKT. Western Blot of MARCKS, ERK, ribosomal S6 and AKT phosphorylation following drug treatments for 24 hrs. α-Tubulin was used as a loading control.

29593251 22653968
Growth inhibition assay
Cell viability ; 

PubMed: 22653968     


AEB071 selectively reduced viability of UM cells harboring GNAQ mutations. Cells were treated with varying amount of AEB071 for 72 hours. Data are presented as mean±SD of 4 or 5 independent experiments. NM = normal melanocytes; WT = GNAQ wild type; MT = G䲧疝Ỵ疞㧀疜膉

22653968
体内研究 AEB071(80 mg/kg) 可以在体内显著抑制SCID的皮下TMD8移植模型肿瘤的生长。[2] 每日两次口服10 mg/kg 和30 mg/kg AEB071,能延长心脏移植的大鼠的存活率,这种作用是剂量依赖抑制免疫力的效应。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[3]
- 合并
  • Animal Models: 雄性 Wistar/F大鼠
  • Dosages: 10 mg/kg 和 30 mg/kg
  • Administration: 口服一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 87 mg/mL (198.41 mM)
Water Insoluble
Ethanol '2 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 438.48
化学式

C25H22N6O2

CAS号 425637-18-9
储存条件 粉状
溶于溶剂
别名 AEB071

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02273219 Unknown status Drug: AEB071|Drug: BYL719 Uveal Melanoma Richard D. Carvajal|Columbia University November 2014 Phase 1
NCT01801358 Terminated Drug: AEB071|Drug: MEK162 Uveal Melanoma Array BioPharma August 2013 Phase 1|Phase 2
NCT01430416 Completed Drug: AEB071 Uveal Melanoma Novartis Pharmaceuticals|Novartis December 20 2011 Phase 1
NCT01402440 Terminated Drug: AEB071 Diffuse Large B-Cell Lymphoma Novartis Pharmaceuticals|Novartis November 2011 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Could you give me the information about how to prepare Sotrastaurin for oral administration in mice?

  • 回答:

    S2791 Sotrastaurin can be dissolved in 2% DMSO/30% PEG 300/ddH2O at 10 mg/ml as a clear solution which can be used for injection, and in 2% DMSO/corn oil at 10 mg/ml as a suspension for oral administration.

PKC Signaling Pathway Map

PKC Inhibitors with Unique Features

相关PKC产品

Tags: 购买Sotrastaurin | Sotrastaurin供应商 | 采购Sotrastaurin | Sotrastaurin价格 | Sotrastaurin生产 | 订购Sotrastaurin | Sotrastaurin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID